share_log

HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $51

HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $51

HC Wainwright公司維持對syndax pharmaceuticals的買入評級,將目標股價上調至51美元
Benzinga ·  2024/11/18 07:00  · 評級/大行評級

HC Wainwright & Co. analyst Edward White maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $49 to $51.

HC Wainwright分析師Edward White維持對syndax pharmaceuticals(納斯達克:SNDX)的買入評級,並將目標股價從49美元上調至51美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論